Company Filing History:
Years Active: 2009-2017
Title: Innovations of Marc De Smet in Pharmacological Vitreolysis
Introduction
Marc De Smet is a notable inventor based in Amstelveen, Netherlands. He has made significant contributions to the field of ophthalmology, particularly through his innovative patents. With a total of 10 patents to his name, De Smet has focused on developing methods that enhance eye treatment and care.
Latest Patents
One of his latest patents is titled "Pharmacological Vitreolysis." This invention presents a method for treating or preventing disorders of the eye by using a composition that includes a truncated form of plasmin. The method involves contacting the vitreous and/or aqueous humor with this composition, which can include miniplasmin, microplasmin, and their derivatives. The applications of this invention are extensive, as it can reduce the viscosity of the vitreous, liquefy it, induce posterior vitreous detachment, and clear toxic materials from the eye. Additionally, it can be used to enhance the diffusion of other compositions administered to the eye and reduce extraretinal neovascularization. This method can be applied independently or as an adjunct to vitrectomy.
Career Highlights
Throughout his career, Marc De Smet has worked with prominent companies in the medical field, including Thrombogenics NV and Oxurion NV. His work in these organizations has allowed him to collaborate with other experts and contribute to advancements in eye care.
Collaborations
Some of his notable coworkers include Steve Pakola, who has also played a significant role in the development of innovative treatments in ophthalmology.
Conclusion
Marc De Smet's contributions to pharmacological vitreolysis represent a significant advancement in the treatment of eye disorders. His innovative methods and collaborations have the potential to improve patient outcomes in ophthalmic care.